DaVita is a regulated-duopoly cash compounding machine: steady dialysis economics + scaling value-based kidney care + relentless buybacks—tempered by payer-mix and policy risk.
Overview
DaVita is a leading U.S.-centric kidney care provider built around a large outpatient dialysis network and an increasingly important value-based care platform. As of Q1 2026, it operates 3,262 outpatient dialysis centers globally (2,666 U.S.; 596 across 14 international markets). The U.S. dialysis segment remains the core earnings engine (~88% of revenue), complemented by ancillary services (lab, pharmacy, vascular access). The business model is primarily per-treatment reimbursement, with a stable but regulated base from government payers (Medicare/Medicaid ~67% of U.S. dialysis revenue) and a crucial profitability kicker from commercial insurance (roughly ~10% of patient volume but disproportionately high margin). Strategically, DaVita is shifting from a pure procedure provider to a longitudinal care manager via Integrated Kidney Care (IKC), managing ~62,600 patients under risk-based arrangements (~$5.4B annualized medical spend). Clinically, DaVita delivers in-center hemodialysis, home modalities (peritoneal dialysis and home hemodialysis), and inpatient services; its “Home First” initiative has moved ~16% of patients to home therapies by 2026. The company’s moat is anchored in scale and clinic density, nephrologist relationships reinforced through physician-owned joint ventures, high patient switching costs, and regulatory barriers to new supply. Technology is a meaningful enabler (OneView EMR and AI-driven scheduling/workflow tools), improving outcomes and productivity, but also increases cyber sensitivity given the impact of the 2025 ransomware event.